Samaritan reports positive preliminary results of 10-day HIV trial

By Elaine Rigoli

Tampa, Fla., May 30 - Samaritan Pharmaceuticals Inc. announced its preliminary results showing antiviral activity in only 10 days with its phase 2 10-day monotherapy study where SP-01A, an oral entry inhibitor, was tested "alone" in patients experiencing HIV drug resistance.

Samaritan said the double-blind, placebo controlled, multi-dose study assessed SP-01A's safety and effect on viral load in HIV-1 positive individuals, with evidence of increasing viral load, despite treatment with antiretroviral therapy.

In the preliminary finding, SP-01A was found to have a 0.4 log10 difference between the high dose group (800 mg/day) and the placebo control group.

In addition, there was a dose-dependent relationship in the number of subjects who had a reduction in viral load with the high-dose group (800 mg/day) showing the most difference as compared to a placebo (55% vs. 0%, respectively), according to a news release.

Located in Las Vegas, Samaritan develops therapeutics for AIDS, Alzheimer's, cancer and heart-disease patients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.